Intezyne patent strategy builds value, appeal to investors

Kevin Sill has a laser-like focus on protecting corporate intellectual property at Intezyne Technologies. He is a co-founder of the Tampa company and its chief science officer. Dovetailing with those jobs and reflecting the importance of Intezyne’s intellectual property, Sill is also a registered patent agent and directs the corporate intellectual property strategy. The 13-employee company, which specializes in developing drug delivery technologies, racked up eight U.S. patents in 2012, the base…